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To the best of our knowledge, this is the ﬁrst report of an undifferentiated pleomorphic sarcoma
arising from a renal graft. Transplantectomy was performed in a 47-year old woman presenting to
the emergency room because of general weakness. Preoperative workup revealed a 5.5 cm
malignant mass of the graft which was not present on routine ultrasound performed 12 months
earlier. Following transplantectomy, local recurrence developed despite complete tumor resection
and interruption of immunosuppression. Despite radiation therapy, the outcome was ultimately
fatal. Genetic analysis revealed that the tumor had arisen from donor tissue. Annual ultrasound
surveillance might not be enough effective to screen for these rare high grade neoplasms.
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uge.ch (G. Mayor).1. Introduction
Renal transplant recipients (RTR) are at an increased risk of
developing renal cancer [1,2]. De novo renal neoplasms
develop after renal transplantation and they arise either from
a native kidney or from the graft. This latter situation is much
less frequent [1]. Less than 100 cases have been reported.
Roupret evaluated a renal clear cell cancer (RCC) cumulative
incidence of 0.24% among RTR population [3]. Most of these
malignancies are RCC but papillary types 1 and 2, tubulopa-
pillary, chromophobic, sarcomatoid, epidermoid and urothelial
carcinomas and oncocytomas have been described [4–8].en access article under the CC BY-NC-ND license
Table 1 Immunomarker pattern.
Marker Biopsy Specimen
Vimentin + +
NSE n.a. +
CD99 + +
VS38C + n.a.
t22q12 – n.a.
EMA – –
Total keratin – –
CK 7 – n.a.
CK 20 – n.a.
CK 903 – n.a.
Uroplakin – n.a.
LCA – n.a.
CD 3 – n.a.
CD 20 – n.a.
CD 34 n.a. –
CD 56 – n.a.
CD 57 n.a. –
CD 128 – n.a.
S-100 – –
Melan A – n.a.
HMB 45 – n.a.
AML n.a. –
Desmin n.a. –
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dilemma. On the one hand, radical treatment requires
allograft nephrectomy and return to dialysis. On the other
hand, interruption of immunosuppression may conceptually
favor the host’s immune response. Current guidelines recom-
mend that any solid renal tumor should be treated with
partial or radical nephrectomy [9]. Percutaneous radiofre-
quency and cryoablation represent alternative treatments in
speciﬁc cases [10–12].
Many uncertainties on allogenic tumors remain due to
their rarity. In this context, we report the case of an
undifferentiated pleomorphic sarcoma arising from a renal
transplant. To the best of our knowledge, no such a case has
been reported up to now.
2. Material and methods (molecular
identiﬁcation of the tumor’s origin)
Extraction of DNA was performed from parafﬁn blocks by the
phenol–chloroform technique. DNA extracts were quantiﬁed
using a Nanodrop spectrophotometer ND-100. 0.5 ng of
extracted DNA was ampliﬁed on a GeneAmps 9700 PCR
thermal cycler (Applied Biosystems), using the AmpF/STRs
SMG Pluss PCR ampliﬁcation kit (Applied Biosystems),
according to the manufacturer’s instructions. Ampliﬁed pro-
ducts were separated on a 3130XL Genetic Analyser (Applied
Biosystems) and analysis of DNA proﬁles was undertaken
using GeneMapper TM ID version 3.2 (Applied Biosystems).
3. Case report
A 43-year-old woman underwent deceased renal transplan-
tation for terminal renal failure secondary to polycystic
kidneys disease. She was placed on tacrolimus and myco-
phenolate and her evolution was unremarkable during
4 years. Then, she showed up at the Emergency Department
of our institution with general weakness. Physical examina-
tion was normal. Laboratory studies revealed acute kidney
failure. A non-enhanced abdominal CT-scan showed a suspi-
cious 5.5 cm mass of the inferior pole of the grafted kidney
compressing the excretory system and two enlarged right
external iliac lymph nodes. Abdominal MRI conﬁrmed a
tissular heterogeneous mass responsible for hydronephrosis.
Chest X-ray and 99 m-Tc-HDP bone scintigraphy were nega-
tive. The patient underwent ureteropyelography with
double-J stenting and biopsies which revealed a malignant
undifferentiated cancer with a distinct immunomarker
pattern (Table 1). She underwent transplantectomy, iliac
and ilio-obturator lymphadenectomy and segmental iliac
artery resection. A 2-cm tumor thrombus was extracted
from the iliac vein.
Gross ﬁndings of the surgical specimen consist of a
whitish heterogeneous mass 5.5 5.5 5 cm3, studded with
hemorrhagic areas, with a capsular effraction and perirenal
adipose tissue inﬁltration. The tumor compresses the pye-
localiceal system and the proximal ureter. Large sampling of
the tumor showed a diffuse highly cellular proliferation of
pleomorphic and fusiform cells arranged often patternless.
Mitosis were abundant (43 mitosis/10 high power ﬁelds;
Mib1 was approximately 60%). Conﬂuent necrosis was observed.
Peritumoral parenchyma was atrophic. Immunohistochemicalanalysis shows diffusely or focally positive stainings for vimen-
tin, NSE, and CD99. Epithelial (keratin, EMA), muscular (des-
min, AML) and vascular (CD34) markers were all negative, as CD
57 and S-100 (see Table 1). Four iliac lymph nodes were invaded
by the tumor. It could be explained by the local seeding of
tumoral cells. We considered the surgical specimen as an
undifferentiated renal pleomorphic sarcoma, grade 3 (FNCLCC
classiﬁcation). The TNM stage was pT2 pN1 cM0 pV1 pR0. The
transplantectomy specimen and histology slides are shown in
Figure 1.
We used STR loci analysis to determine the tumor’s origin
(graft versus host). The tumoral tissue showed LOH at the
D3S1358, D16S539 and vWA loci. Microsatellite instability
was seen with a new allele 13 at the vWA locus (Figure 2).
No STR instability was observed at the other 7 loci analyzed.
As the tumor mirrored the genetic instability of the donor’s
DNA and not that of the receiver’s DNA, we concluded that
the cancer originated from the donor’s kidney.
Four weeks following surgery, an 18-FDG thoraco-abdom-
inal PET-CT showed an intense hypermetabolic signal inﬁl-
trating the right psoas muscle and the iliac vessels with
suspect retroperitoneal lymph nodes suggesting local recur-
rence and lymphatic spread. Ten weeks postoperatively, the
patient underwent a local radiation therapy (60 Gy in 30
fractions). One year postoperatively, PET-CT showed persis-
tent retroperitoneal inﬁltration with a differential diagnosis
of actinic alteration or tumor persistence but no adenome-
galy or distant metastases. The patient died abroad 18
months after transplantectomy. Unfortunately, it was not
possible to obtain further details about the medical cause of
death and a possible dissemination of the disease.
Figure 1 Undifferentiated pleomorphic sarcoma of the kidney. Soft lobulated and pale tumor bulging in the renal pelvis (A). Dense
proliferation of pleomorphic cells with numerous atypia, high mitotic activity and necrosis (B: microscopy hematoxylin–eosin
staining and loop magniﬁcation 100 ).
Figure 2 Electropherograms showing differences at 3 of the 10 STR loci (SGM Plus kit) between the DNA proﬁles of the healthy graft
(upper part of the picture) and the tumoral graft (lower part of the picture). The major component of the mixed DNA proﬁle of the
healthy kidney is from the donor (D) and the minor component from the receiver (R) of the transplant. The tumoral tissue (lower
part) shows a loss of heterozygosity at the D3S1358 locus (allele 16), at the D16S539 locus (allele 12) and at the vWa locus (allele 18).
Microsatellite instability is seen with a new allele 13 at the vWA locus.
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To our knowledge, this is the ﬁrst published case of primary
sarcoma arising from a renal transplant. Despite its vast
extension upon diagnosis, the tumor had not been detected
during routine renal graft ultrasound 1 year before, suggest-
ing rapid growth within short time. The EAU guidelines on
renal transplantation recommend an annual echographic
screening [9]. This case suggests that this surveillance might
not be close enough to detect high-grade sarcomas because
the tumor growth rate appeared to be about 10-times faster
than the growth rate of renal cell carcinomas, which is
estimated to be about 0.5 cm/year [13].
Because of the tumor’s size, partial nephrectomy was not
technically feasible and the patient returned to dialysis.
Despite a R0 resection and the stop of immunosuppression,
which might contribute to stop the growth of allogenic
tumoral cells, there was a quick local recurrence. In our
knowledge, there is no data about radiation therapy as
treatment for local recurrence in renal transplant neo-
plasms. In regards with the 1 year follow-up, our case
suggests a potential beneﬁt for local tumor control within a
short period of time.
5. Conclusion
Renal cancer prevalence in RTR might increase because of
aging of RTR and older donors. Annual ultrasound surveil-
lance might not be effective enough to screen for high-
grade neoplasms. While radical surgery remains the only
potentially curative treatment, adjuvant radiation therapy
might be proposed for local recurrence.
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